[Gulf Resources, Inc. 99 Wenchang Road Chenming Industrial Park Haoyuan Chemical Company Limited, Shouguang City, Shandong, China 262714 Division of Corporation Finance 100 F. Street, N.E. Re: Gulf Resources, Inc. Request for Withdrawal of Registration Statement on Form S-3 (File No.: 333-168591) Ladies and Gentlemen: The Company is requesting such withdrawal because the Company has determined that it does not]
[Gulf Resources, Inc. 99 Wenchang Road Chenming Industrial Park Haoyuan Chemical Company Limited, Shouguang City, Shandong, China 262714 Division of Corporation Finance 100 F. Street, N.E. Re: Gulf Resources, Inc. Request for Withdrawal of Registration Statement on Form S-3 (File No.: 333-168591) Ladies and Gentlemen: The Company is requesting such withdrawal because the Company has determined that it does not]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): July 20, 2011(July 14, 2011) INC. THT HEAT TRANSFER TECHNOLOGY, Nevada 001-34812 20-5463509 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) THT Industrial Park No.5 Nanhuan Road, Tiexi District Siping, Jilin Province 136000 People's Republic of China 86-434-3265241 (Former name or former address, if]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): July 20, 2011(July 14, 2011) INC. THT HEAT TRANSFER TECHNOLOGY, Nevada 001-34812 20-5463509 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) THT Industrial Park No.5 Nanhuan Road, Tiexi District Siping, Jilin Province 136000 People's Republic of China 86-434-3265241 (Former name or former address, if]
[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
